Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Namuscla 167 mg hard capsules

Active Ingredient:
mexiletine hydrochloride
Company:  
Lupin Healthcare (UK) Ltd See contact details
ATC code: 
C01BB02
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Namuscla 167 mg hard capsules-Educational Guide-Minimising the risks of cardiac arrhythmia and severity of adverse reactions in those with hepatic impairment

{healthcare_pro_orange} For Healthcare Professionals
Important information on minimising the risks of cardiac arrhythmia and severity of adverse reactions in those with hepatic impairment
{pdf_link}

Namuscla 167 mg hard capsules-Patient Alert Card-The risk of Cardiac Arrhythmia

Patient Alert Card-The risk of Cardiac Arrhythmia

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Lupin Healthcare (UK) Ltd
Company image
Address
The Urban Building, 2nd Floor, 3-9 Albert Street, Slough, SL1 2BE
WWW
www.lupinhealthcare.co.uk
Telephone
+44 (0)1565 751 378
Fax
+44 (0)1565 751 379
Medical Information Direct Line
+44 (0)1565 751 378 Option 1
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)1565 751 378
Stock Availability
+44 (0)1565 751 378
Drug Safety Telephone
+44 (0) 1565 751378 Option 1
Drug Safety e-mail
[email protected]